Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

DiagnoseOne (Nashua, NH) a commercial-stage healthcare informatics company focused on clinical decision support software, closed a $5M Series B financing. Participants include Edison Venture Fund.

Cara Therapeutics (Shelton, CT) a clinical-stage small molecule company focused on pain and inflammation, closed a $15M Series D financing. Participants include Rho Ventures, Alta Partners, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Mitsubishi International and MVM Life Science Partners.

Euthymics Bioscience (Cambridge, MA) a clinical-stage small molecule company focused on CNS disorders and depression, closed a $24M Series A financing. Participants include Novartis Venture Fund, Venture Investors, H&Q Capital Management and GBS Venture Partners.

And cue the confetti cannon as we celebrate the 1,000th OnBioVC.com post! AxioMed Spine (Cleveland, OH) a clinical-stage medical device company focused on lumbar disc replacement, closed a $15M Series D financing. Participants have included Thomas, McNerney & Partners, CID Equity Partners, Early Stage Partners, Investor Growth Capital, MB Venture Partners, Primus Capital Funds and […]

Immune Design (Seattle, WA) a development-stage therapeutic vaccine company focused on oncology and infectious disease, closed a $32M Series B financing. Participants include ProQuest Investments, Column Group, Versant Ventures and Alta Partners.

SuperDimesnion (Minneapolis, MN) a commercial-stage medical device company focused on minimally invasive distal lung disease treatments, closed a $9.8M Series B financing. Participants include Dan Sullivan Investments, Medica Venture Partners, OrbiMed, Oxford Biosciences Partners and Pitango Venture Capital.

Jennerex Biotherapeutics (San Francisco, CA) a clinical-stage biopharma company focused on an oncolytic poxvirus therapeutic for liver, colon and head & neck cancers, closed a $8.6M Series D financing. Participants were not identified.

ClearCount Medical Solutions (Pittsburgh, PA) a commercial-stage company focused on patient safety with RFID tagged surgical smart sponges for surgical reconciliation and operational efficiency, closed a $5M Series B financing. Participants include Draper Triangle Ventures and Draper Fisher Jurvetson.

Anchor Therapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on peptides to modulate G-protein coupled receptors in oncology, CV and inflammatory diseases, closed a $10M Series B financing. Participants include TVM Capital, HealthCare Ventures and Novartis Option Fund.

Phreesia (New York City, NY) a commercial-stage provider of patient check-in systems, closed a $20M Series D financing. Participants include VantagePoint, Ascension Health Ventures, Polaris Venture Partners, HLM Venture Partners, Long River Ventures and BlueCross BlueShield Venture Partners.

Watermark Medical (Boca Raton, FL) a commercial-stage medical device company focused on sleep apnea, closed a $6M Series B financing. Participants include Ballast Point Ventures.

Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.

Accuri Cytometers (Ann Arbor, MI) a commercial-stage device company focused on flow cytometery solutions for the R&D market, closed a $6M Series E financing. Participants include Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and InvestMichigan.

« Previous Entries  Next Page »

to top of page...